TFE-Altered Renal Cell Carcinoma: A Contemporary Review With Practical Insights and Diagnostic Pearls for Surgical Pathologists.
Since the initial recognition of unique renal cell carcinomas (RCC) with the ASPCR1::TFE3 gene fusion, the category of MiT-family RCC has evolved to include TFE3 -rearranged RCC, TFEB -rearranged RCC,
APA
Przybycin CG, Nguyen JK, Alaghehbandan R (2026). TFE-Altered Renal Cell Carcinoma: A Contemporary Review With Practical Insights and Diagnostic Pearls for Surgical Pathologists.. Advances in anatomic pathology, 33(2), 155-166. https://doi.org/10.1097/PAP.0000000000000519
MLA
Przybycin CG, et al.. "TFE-Altered Renal Cell Carcinoma: A Contemporary Review With Practical Insights and Diagnostic Pearls for Surgical Pathologists.." Advances in anatomic pathology, vol. 33, no. 2, 2026, pp. 155-166.
PMID
41574499
Abstract
Since the initial recognition of unique renal cell carcinomas (RCC) with the ASPCR1::TFE3 gene fusion, the category of MiT-family RCC has evolved to include TFE3 -rearranged RCC, TFEB -rearranged RCC, and TFEB -amplified RCC, 3 entities with significant intracategory and intercategory variation in morphology and clinical behavior. Given their ability to mimic one another as well as more common RCC subtypes, we present a review here that summarizes relevant morphologic, immunohistochemical, and molecular findings as well as a practical approach to diagnosis. Accurate diagnosis of TFE-altered RCCs is critical to provide patients and treating clinicians with pertinent prognostic information and inform treatment decisions in the event of advanced disease.
MeSH Terms
Humans; Carcinoma, Renal Cell; Kidney Neoplasms; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Biomarkers, Tumor; Pathology, Surgical; Immunohistochemistry